Determination of KD025 (SLx-2119), a Selective ROCK2 Inhibitor, in Rat Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry and Its Pharmacokinetic Application

KD025 (SLx-2119), the first specific Rho-associated protein kinase 2 (ROCK2) inhibitor, is a potential new drug candidate currently undergoing several phase 2 clinical trials for psoriasis, idiopathic pulmonary fibrosis, chronic graft-versus-host disease, and systemic sclerosis. In this study, a bio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Jin-Ha, Nguyen, Thi-Thao-Linh, Duong, Van-An, Chun, Kwang-Hoon, Maeng, Han-Joo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144358/
https://www.ncbi.nlm.nih.gov/pubmed/32192179
http://dx.doi.org/10.3390/molecules25061369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144358/
https://www.ncbi.nlm.nih.gov/pubmed/32192179
http://dx.doi.org/10.3390/molecules25061369

Ejemplares similares